Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
| ▸ | PNMT | P11086 | 5/20 | 0.38 |
| ▸ | CD44 | P16070 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.34 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29772412 | 1.00 | POLB (0.43) | POLBSMN1; SMN2HTR2CCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL31126075 | 0.98 | POLB (0.42) | POLBSMN1; SMN2HTR2CCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL7009520 | 0.98 | POLB (0.42) | POLBSMN1; SMN2HTR2CCHRNB2CHRNA4 | |
| Bicarbonate SCHEMBL28884573 | 0.90 | ATR (0.39) | POLBSMN1; SMN2HTR2CCHRNB2CHRNA4 | |
| SCHEMBL2453582 | 0.89 | POLB (0.35) | POLBSMN1; SMN2HTR2CCHRNB2CHRNA4 | |
| SCHEMBL2342848 | 0.86 | CHRNB2 (0.48) | HTR2CCHRNB2CHRNA4 | |
| SCHEMBL397493 | 0.84 | HTR2C (0.46) | POLBSMN1; SMN2HTR2CCHRNB2CHRNA4 | |
| SCHEMBL29428686 | 0.84 | HTR2C (0.46) | POLBSMN1; SMN2HTR2CCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL6438259 | 0.84 | CHRNB2 (0.47) | HTR2CCHRNB2CHRNA4 | |
| Hydrochloric Acid SCHEMBL6767466 | 0.82 | HTR2C (0.45) | POLBSMN1; SMN2HTR2CCHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 288 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11434247-B1 | Substituted furanopyrimidine compounds as PDE1 inhibitors | DART NEUROSCIENCE LLC (US) | 2022-09-06 | — | — | US | claimed |
| EP-3717488-B1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2021-09-29 | — | — | EP | claimed |
| EP-3717488-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | Dart NeuroScience, LLC (US) | 2020-10-07 | — | — | EP | claimed |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | VALO HEALTH, INC. | 2020-09-15 | — | — | US | claimed |
| CN-111655695-A | Substituted furopyrimidines as PDE1 inhibitors | 达特神经科学有限公司 | 2020-09-11 | — | — | CN | claimed |
| CN-105712974-B | Certain amino-pyrimidines, compositions thereof and methods of use thereof | 赛特凯恩蒂克公司 | 2020-07-31 | — | — | CN | claimed |
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-10-29 | — | — | US | claimed |
| WO-2019104285-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2019-05-31 | — | — | WO | claimed |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | claimed |
| US-20190105307-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Valo Health, LLC | 2019-04-11 | — | — | US | claimed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | claimed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | claimed |
| EP-2734521-A1 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS | Novartis AG (CH) | 2014-05-28 | — | — | EP | claimed |
| EP-2611804-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | Forma TM, LLC. (US) | 2013-07-10 | — | — | EP | claimed |
| WO-2013016197-A1 | TETRAHYDROPYRIDO-PYRIDINE AND TETRAHYDROPYRIDO-PYRIMIDINE COMPOUNDS AND USE THEREOF AS C5A RECEPTOR MODULATORS | NOVARTIS AG (CH) | 2013-01-31 | — | — | WO | claimed |
| WO-2012031197-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA THERAPEUTICS, INC. (US) | 2012-03-08 | — | — | WO | claimed |
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | claimed |
| EP-4737470-A2 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | Zikani Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-0337944-B1 | UREAS | CIBA-GEIGY AG (CH) | 1993-07-28 | — | — | EP | disclosed |
| EP-0337944-A1 | Ureas | CIBA-GEIGY AG (CH) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11434247-B1 | Substituted furanopyrimidine compounds as PDE1 inhibitors | PDE4A, PDE5A, PDE3A | POLB 1067/4885SMN1; SMN2 68/4885HTR2C 2093/4885 |
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | JAK2, JAK1, JAK3 | POLB 2062/4885SMN1; SMN2 4368/4885HTR2C 2915/4885 |
| US-20190105307-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | POLB 2930/4885SMN1; SMN2 1497/4885HTR2C 3033/4885 |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | POLB 2930/4885SMN1; SMN2 1497/4885HTR2C 3033/4885 |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | POLB 2930/4885SMN1; SMN2 1497/4885HTR2C 3033/4885 |
| US-10772874-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | POLB 1931/4885SMN1; SMN2 1001/4885HTR2C 3002/4885 |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | POLB 1931/4885SMN1; SMN2 1001/4885HTR2C 3002/4885 |
| US-10456382-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | POLB 1931/4885SMN1; SMN2 1001/4885HTR2C 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.